Innate Pharma Reports GAAP EPS of -€0.31 with Revenue of €12.35M – Key Insights
Thursday, 12 September 2024, 05:15
Key Financial Results of Innate Pharma
Innate Pharma (IPHA) has recently shared its financial performance for the first half. Below are the highlights:
- GAAP EPS: -€0.31
- Revenue: €12.35M
- Year-over-Year Revenue Change: -69.3%
Implications for Investors
Investors need to evaluate how Innate Pharma's current financial stance may influence stock performance. Factors such as market conditions, upcoming trials, and potential partnerships will play a crucial role in shaping future growth.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.